Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0bb81e79f57cc54fa2aa6affbd579b5b http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_382ccfc2ebebcaee15aa7cda4cee86bc http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_14a56e82e7ee8111cfcd7565412176b3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_27b5d54fadec3dba85ffaf197aba2ffa http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ff4a5f409f2d3d0bc3c7815473c40725 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-185 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-353 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-352 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-045 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-352 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-185 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-08 |
filingDate |
2012-09-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3a30f424279079560606a3abb47840eb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e955a6d69a3f1b6376fc66ab924e85d2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c0a358aabaf43803a1cae94820457b81 |
publicationDate |
2013-04-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-2013045891-A1 |
titleOfInvention |
A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (cbdv) and cannabidiol (cbd) |
abstract |
This invention relates to a pharmaceutical composition comprising or consisting essentially of the phytocannabinoids cannabidivarin (CBDV)and cannabidiol (CBD). The composition is particularly safe and efficacious for use in the treatment of neurological conditions, characterized by hyper-excitability of the central nervous system, convulsions or seizures such as occur in epilepsy. Preferably the CBDV and the CBD are present with at least one non- cannabinoid component of cannabis such as one or more terpenes or a terpene fraction. More particularly the composition further comprises one or more cannabichromene type compounds. Particularly cannabichromene propyl variant (CBCV) and / or cannabichromene (CBC).More particularly still the composition is absent or substantially absent of other cannabinoids, including in particular tetrahydrocannabinol (THC) and tetrahydrocannabivarin (THCV), which would normally be present in significant amounts in cannabis chemotypes bred to contain a significant amount of CBDV and / or CBD. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020225540-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016187679-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11779562-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022180379-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3735964-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11701330-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10537592-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11633369-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10383892-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10799467-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10143706-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10857107-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11147776-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10653640-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11766411-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11318096-B2 |
priorityDate |
2011-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |